Yes, I thought that quote was encouraging, but after the annual meeting comments, I'm preparing for later in the year to get CMC portion of the BLA filed. Maybe NP has / is finally learning to under-promise and we will be pleasantly surprised if it comes sooner.

Another quote I thought important/encouraging: "across the various extension trials, there are now over 150 HIV treatment-resistant patients that have been exclusively on Leronlimab (PRO140) monotherapy for over one year."

And one not so much (I didn't think they would have a drug resistant label for mono): "The company also plans to initiate a 48-week Phase 3 registration study of Leronlimab (PRO140) as a monotherapy for drug resistant HIV patients"